中国苏州，13 价肺炎球菌结合疫苗使用前儿童侵袭性肺炎球菌病住院情况。

Emerg Infect Dis. 2021 Jan;27(1):69-75. doi: 10.3201/eid2701.181415.

A 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease (IPD) was introduced in China in April 2017. We describe 105 children <5 years of age who were hospitalized for IPD at Soochow University Affiliated Children's Hospital in Suzhou, China, during January 2010-December 2017. We calculated the incidence of hospitalization for IPD as 14.55/100,000 children in Suzhou. We identified 8 different capsular serotypes: 6B (28.4% of cases), 14 (18.9% of cases), 19A (18.9% of cases), 19F (12.2% of cases), 23F (10.8% of cases), 20 (4.1% of cases), 9V (4.1% of cases), and 15B/C (2.7% of cases). These results provide baseline data of IPD before the introduction of this vaccine in China, enabling researchers to better understand its effects on IPD incidence.

2017 年 4 月，中国开始使用 13 价肺炎球菌结合疫苗预防侵袭性肺炎球菌病（IPD）。我们描述了 2010 年 1 月至 2017 年 12 月期间在苏州大学附属儿童医院住院的 105 名年龄小于 5 岁的 IPD 患儿。我们计算出苏州的 IPD 住院发病率为 14.55/100,000 名儿童。我们确定了 8 种不同的荚膜血清型：6B（28.4%的病例）、14（18.9%的病例）、19A（18.9%的病例）、19F（12.2%的病例）、23F（10.8%的病例）、20（4.1%的病例）、9V（4.1%的病例）和 15B/C（2.7%的病例）。这些结果提供了该疫苗在中国使用前 IPD 的基线数据，使研究人员能够更好地了解其对 IPD 发病率的影响。